These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 17190395)

  • 21. The Food and Drug Administration's regulation of drug labeling, advertising, and promotion: looking back and looking ahead.
    Hayes TA
    Clin Pharmacol Ther; 1998 Jun; 63(6):607-16. PubMed ID: 9663174
    [No Abstract]   [Full Text] [Related]  

  • 22. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 23. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 24. US Senate passes FDA Revitalization Act.
    Guthrie P
    CMAJ; 2007 Jul; 177(1):23. PubMed ID: 17606930
    [No Abstract]   [Full Text] [Related]  

  • 25. Report hits FDA to revamp safety oversight.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Jul; 98(13):884-5. PubMed ID: 16818849
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug-review deadlines and safety problems.
    Nardinelli C; Lanthier M; Temple R
    N Engl J Med; 2008 Jul; 359(1):95-6; author reply 96-8. PubMed ID: 18596282
    [No Abstract]   [Full Text] [Related]  

  • 27. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 29. Validation--mission completed?
    Sharp J
    J Parenter Sci Technol; 1993; 47(1):2-3. PubMed ID: 8445494
    [No Abstract]   [Full Text] [Related]  

  • 30. Lessons from Eprex for biogeneric firms.
    Louët S
    Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539
    [No Abstract]   [Full Text] [Related]  

  • 31. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J
    Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
    [No Abstract]   [Full Text] [Related]  

  • 32. Needed: an intervention. Drug industry's control of health policy must be broken.
    Sloane T
    Mod Healthc; 2004 Nov; 34(48):18. PubMed ID: 15605785
    [No Abstract]   [Full Text] [Related]  

  • 33. Blowing the whistle at the FDA.
    Simons J
    Fortune; 2005 Jan; 151(2):32. PubMed ID: 15693304
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug safety: a contrarian's point of view.
    Cobert B
    Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392
    [No Abstract]   [Full Text] [Related]  

  • 35. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.
    Qato DM; Alexander GC
    JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303
    [No Abstract]   [Full Text] [Related]  

  • 36. Post-marketing strategies for medicines.
    Breckenridge A
    Clin Pharmacol Ther; 2008 Jan; 83(1):24-5; discussion 25. PubMed ID: 18043682
    [No Abstract]   [Full Text] [Related]  

  • 37. Striking the right balance.
    Nat Rev Drug Discov; 2006 Nov; 5(11):879. PubMed ID: 17117516
    [No Abstract]   [Full Text] [Related]  

  • 38. FDA transparency rules could hit small companies hardest.
    Allison M
    Nat Biotechnol; 2010 Aug; 28(8):767-8. PubMed ID: 20697386
    [No Abstract]   [Full Text] [Related]  

  • 39. The drug safety system conundrum.
    Tiedt TN
    Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmaceutical postmarket review: fact or fiction?
    Schanz SJ
    Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.